

Innovative Therapies for Back of the Eye Disorders : Developing Disease Modifying Treatments for Diabetic Eye Disease

Patrik De Haes, MD, CEO
VFB, Gent, 29 September 2018



ADVANCING SCIENCE.®
ENHANCING VISION.



Forward-looking statement

This document has been prepared by Oxurion NV (the "Company") and is being supplied to you solely for your information and use by you at the Company presentation. This document and its contents are confidential and may not be further distributed or passed on to any other person or published or reproduced, in whole or in part, by any medium or in any form for any purpose. All the numerical data provided in this document are derived from Oxurion consolidated financial statements.

No representation or warranty expressed or implied is or will be made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the information or opinions contained herein. The information set out herein may be subject to updating, completion, revision, verification, and amendment, and such information may change materially. The Company is under no obligation to update or keep current the information contained in this document or the presentation to which it relates, and any opinions expressed in it are subject to change without notice. None of the Company or any of its affiliates, its advisors, or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this document or its contents or otherwise arising in connection with this document.


The following information does not constitute investment advice, and shall not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Oxurion value proposition today : the Core ... and more




Diabetic retinopathy


NORMAL RETINA



DIABETIC RETINOPATHY




Diabetic Macula Edema



Diabetic eye disease

More than one in three people living with diabetes will develop some form of diabetic retinopathy in their lifetime, being a leading cause of vision loss in working-age adults



* Vision-threatening DR is defined as the presence of PDR and/or DME

Abbreviation(s): DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; DME, diabetic macular edema

Source(s): International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. <http://www.diabetesatlas.org>; Kourgialis N. International Agency for the Prevention of Blindness. Vision Atlas. <http://atlas.iapb.org/vision-trends/diabetic-retinopathy/>; Yau JW et al. *Diabetes Care* 2012;35:556-564

Diabetic macular edema treatment options & challenge

Although anti-VEGF therapy is the mainstay of treatment in DME, unresolved challenges highlight the substantial unmet medical need in this disease

Limited treatment options

- Intravitreal anti-VEGF injections
- Intravitreal sustained release corticosteroid injections
- Laser therapy

Unresolved challenges


- Better treatment outcomes (improved efficacy, safety, patient-related outcomes, etc.)
- Poor or sub-optimal responder patients to current standard of care
- Treatment burden with intravitreal anti-VEGF treatments (frequency & durability)

Abbreviation(s): VEGF, vascular endothelial growth factor; DME, diabetic macular edema

Source(s): Wells JA et al. *N Engl J Med* 2015;372:1193-1203; Wells JA et al. *Ophthalmology* 2016;123:1351-1359; Shah AR et al. *J Vitreoretin Dis* 2017;1:169-174

Oxurion Ophthalmology portfolio

Diabetic Retinopathy / Diabetic Macular Edema / MacTel1





An Oxurion venture developing next immuno-oncology therapies for broad application




Recent Oncurious Development – Next Generation Immuno-Oncology

Exciting pipeline of next-generation immuno-oncology drugs targeting a broad spectrum of cancers

- Phase 1 /2 a clinical trial evaluating TB-403 for relapsed medulloblastoma (finalizing 3rd dose level) – data mid 2019 with intermediate update Q1 19
- Oncurious and VIB developing pipeline of 5 next-generation immuno-oncology compounds targeting a broad spectrum of cancers: preclinical PoC by end of 2019
- Oncurious venture partners: VIB / Oxurion hold 15% and 85% respectively

Oncurious : oncology portfolio

Pediatric brain cancer (Medulloblastoma)/ Next gen Immuno Oncology (Broad Spectrum Onco)



Oxurion – Investment highlights

- **Forging new directions in diabetic eye disease**
 - Targeting multiple disease-modifying pathways
 - Enhancing & going beyond vascular endothelial growth factor (VEGF) inhibition
- **Near-term (2019!) value drivers: robust pipeline and strong research engine**
 - 4 proprietary programs in the clinic - key readouts mid 2019
 - 1 advanced preclinical program
 - Oncurious – Clinical study read out in 2019 + optionality of broad immuno-oncology pipeline
- **End-to-end: proven ability to discover, develop and commercialize ophthalmology therapies**
 - Jetrea[®] - First-ever therapeutic for treatment of vitreomacular adhesion & traction
 - More than 30,000 patients treated to date
- **Solid financial position**
 - €101.4 cash on hand end-June, 2018
- **80 employees globally, HQ in Leuven (BE), US office in Iselin, NJ**
- **Experienced management team with big pharma and biotech experience**

Thank you